Outcome of Board Meeting held on November 05, 2026 for considering unaudited financial results for the quarter and half year ended on September 30, 2026.

STARSOURCE MULTITRADE LIMITED (Formerly known as Chemo Pharma Laboratories Limited) (CIN: L46900MH1942PLC003556) Date: November 05, 2026 Bombay Stock Exchange Limited Department of Corporate Services, 25th Floor, P. J. Towers, Dalal Street, Mumbai-400001 Script Id: 506365 ISIN: INE320M01019 Subject: Outcome of Board Meeting held on November 05, 2026. Dear Sir / Madam, Pursuant to Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirement) Regulations, 2015, we wish to inform you that Board of Directors of the Company at their meeting held on Thursday, November 05, 2026 at the Registered Office of the Company, inter alia, have considered and approved Un-Audited Standalone Financial Results of the Company for the second quarter ended September 30, 2026. In this regards, we are enclosing herewith : 1. Un-Audited Standalone Financial Results of the Company for the second quarter ended September 30, 2026, along with Limited Review Report thereon. 2. Statement of Assets & Liabilities and Cash Flow as on September 30, 2026 (Standalone). 3. Non-Applicability of Regulation 23(9) of SEBI (LODR) (Amendments) Regulation, 2018 4. Declaration/Disclosure regarding under Regulation 33(2)(a) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The aforesaid information will also be made available on website of the company. The meeting commenced at 01:45 PM and concluded at 02:15 PM. The same may please be taken on record. Thanking You. Yours Faithfully, FOR Starsource Multitrade Limited (Formerly known as Chemo Pharma Laboratories Limited) RUCHIT MEHTA Managing Director & Chief Executive Officer DIN: 08810586 Registered Office: 5 - Kumud Apartment CHS Ltd, Karnik Road, Chikan Ghar, Kalyan,– 421301, India Corporate Headquarter: 1016, North Plaza, Near D Mart, Motera, Ahmedabad– 380005, India Ph: +91-22-22078381 / 82 | Fax: +91-22-22074294 Email: chemopharmalaboratorieslimited@gmail.com | www.starsourcemultitrade.com STARSOURCE MULTITRADE LIMITED ( Formerly known as Chemo Pharma Laboratories Limited ) CIN: L 4 6 9 0 0 M H 1 9 4 2 P L C 0 0 3 5 5 6 Registered Office: 5 - Kumud Apartment CHS Ltd, Karnik Road, Chikan Ghar, Kalyan,– 421301, India Statement of audited Standalone Financial Results for the Quarter ended September 30, 2026 ( Rs. In Thousands ) For The Year Quarter Ended Half year ended Particulars Ended 30-09-2026 30-06-2026 30-09-2025 30-09-2026 30-09-2025 31-03-2026 A Date of start of reporting period 01-07-2026 01-04-2026 01-07-2025 01-04-2026 01-04-2025 01-04-2025 B Date of end of reporting period 30-09-2026 30-06-2026 30-09-2025 30-09-2026 30-09-2025 31-03-2026 C Whether results are audited or unaudited Unaudited Unaudited Unaudited Unaudited Unaudited Audited 1 Income (a) Revenue From Operations - 745.85 5,256.56 745.85 5,256.56 5,256.56 (b) Other Income - - - 207.12 238.86 Total Income - 745.85 5,256.56 745.85 5,463.68 5,495.42 2 Expenditure - (a) Cost of materials consumed - - - - - - (b) Purchases of stock-in-trade - - 3,765.35 - 3,765.35 3,765.35 (c) Changes in inventories of finished goods, work-in- progress and - - - - - - stock-in-trade (d) Employee benefit expense 178.50 288.00 216.00 466.50 456.60 888.60 (e) Finance Costs 1.75 0.31 0.59 2.06 5.97 9.81 (e) Depreciation and amortisation expense 1.35 1.35 - 2.70 - 3.48 (f) Other Expenses 440.66 246.35 294.48 687.01 1,18,306.27 1,19,377.10 Total expenses 622.27 536.01 4,276.43 1,158.28 1,22,534.19 1,24,044.34 Profit (loss) Before exceptional & Extraordinary items and Tax (622.27) 209.84 980.14 (412.43) (1,17,070.51) (1,18,548.93) Exceptional items - - - - - - Profit (loss) from ordinary activities before tax (622.27) 209.84 980.14 (412.43) (1,17,070.51) (1,18,548.93) Tax Expenses - Current Tax - - - - - - (less):· MAT Credit - - - - - - Current Tax Expense Relating to Prior years - - - - - - Deferred Tax (Assets)/llabtlltles - - - - - 0.80 Profit (loss) from ordinary activities (622.27) 209.84 980.14 (412.43) (1,17,070.51) (1,18,549.73) Other Comprehensive Income (OCI) Items that will not be reclassified to profit or loss Income tax relating to items that will not be reclassified to profit or - - - - - - Items that will be reclassified to profit or loss Income tax relating to items that will be reclassified to profit or loss - - - - - - Total Profit After Other Comprehensive Income (622.27) 209.84 980.14 (412.43) (1,17,070.51) (1,18,549.73) Profit/(Loss) From Discountinuing Operation Before Tax Tax Expenses of Discontinuing Operations Net Profit/(Loss) from Discountinuing Opration After Tax - - - - - - Profit(Loss) For Period Before Minority Interest - - - - - - Share Of Profit / Loss Associates Profit/Loss Of Minority Interset Net Profit (+)/ Loss (-) For the Period (622.27) 209.84 980.14 (412.43) (1,17,070.51) (1,18,549.73) Details of equity share capital Paid-up equity share capital 15,000.00 15,000.00 15,000.00 15,000.00 15,000.00 15,000.00 Face value of equity share capital (per share) 10.00 10.00 2,229.00 0.00 Reserve Excluding Revaluation Reserves As Par Balance sheet Of previous (2,541.77) (1,919.50) (624.51) (2,541.77) (624.51) (2,129.34) Year Earnings per share (EPS) Basic earnings per share from countinuing And Discountinuing (0.41) 0.14 0.65 (0.03) (78.05) (7.90) operations Diluted earnings per share from countinuing And Discountinuing (0.41) 0.14 0.65 (0.03) (78.05) (7.90) operations sr no. Notes TheabovesaidfinanicalresultswerereviewedbytheAuditCommitteeandthenapprovedbytheBoardofDirectorsof thecompanyattheirrespectiveMeetingsheldon November 05, 2026. The statutory auditors of the Company have carried out limited review of the same. 2 The Statutory Auditors have carried out limited review of the Unaudited Results of the Compnay for the Quarter ended 30/09/2026. TheseresultshavebeenpreparedinaccordancewiththeIndianAccountingStandard(referredtoas"IndAS")34-InterimFinancialReportingprescribedunderSection133of the Companies Act, 2013 read with Companies (Indian Accounting Standards) Rules as amended from time to time and considering going concern aussmption. TheCompanyhasnoreportablebusinesssegment.Hence,separateinformationforsegmentwisedisclosureisgiveninaccordancewiththerequirementsof IndAS(AS)108- "Segment Reporting" is not required. 5 The figures for the corresponding previous period have been regrouped/ reclassified wherever necessary, to make them comparable. For,STARSOURCE MULTITRADE LIMITED Mr.Ruchit Mehta (Managing Director) Date : 05/11/2026 DIN : 08810586 Place : Kalyan STARSOURCE MULTITRADE LIMITED ( Formerly known as Chemo Pharma Laboratories Limited ) CIN: L 4 6 9 0 0 M H 1 9 4 2 P L C 0 0 3 5 5 6 Registered Office: 5 - Kumud Apartment CHS Ltd, Karnik Road, Chikan Ghar, Kalyan,– 421301, India Standalone Statement of Balance Sheet as at 30th September, 2026 (Rupees in Thousands) As at As at Particulars 30th September, 2026 31st March, 2026 ASSETS Non-current assets (a) Property, plant and equipment 6 .95 9 .65 (b) Capital work-in-progress - (c) Investment in properties 6 0.75 6 0.75 (d) Financial assets - (i) Investments (ii) Trade receivables (iii) Loan - (e) Deferred Tax Assets (f) Other non-current asset - Total non-current assets 67.71 70.40 Current assets (a) Inventories (b) Financial assets (i) Trade receivables 4 ,884.39 4 ,884.39 (ii) Cash and cash equivalents 1 22.26 (iii) Other bank balance 5 7.02 (iv) Loans & Advances 1 3,196.23 1 3,040.56 (v) Other financial asset - (vi) Deposites 6 2.00 (c) Income/Current tax assets (net) (c) Other current assets Total current assets 1 8,199.63 1 8,047.21 TOTAL ASSETS 1 8,267.34 1 8,117.62 EQUITY AND LIABILITIES Equity (a) Equity share capital 1 5,000.00 1 5,000.00 (b) Other equity (2,515.93) (2,103.50) Total equity 1 2,484.07 1 2,896.50 Non-current liabilities - (a) Financial liabilities - (i) Borrowings (b) Defferred tax liability (net) (87.08) ( 87.08) (c) Other non current liabilities 1 50.00 1 50.00 Total non current liabilities 6 2.92 6 2.92 [Showing first 8,000 characters — download PDF for full document]